Establishing plausibility of cardiovascular adverse effects of immunotherapies using Mendelian randomisation

Le, N. N., Tran, T. Q. B., Du Toit, C. , Gill, D. and Padmanabhan, S. (2023) Establishing plausibility of cardiovascular adverse effects of immunotherapies using Mendelian randomisation. Frontiers in Cardiovascular Medicine, 10, 1116799. (doi: 10.3389/fcvm.2023.1116799) (PMID:37273876) (PMCID:PMC10235787)

[img] Text
286278.pdf - Published Version
Available under License Creative Commons Attribution.

5MB

Abstract

Immune checkpoint inhibitors (ICIs) and Janus kinase inhibitors (JAKis) have raised concerns over serious unexpected cardiovascular adverse events. The widespread pleiotropy in genome-wide association studies offers an opportunity to identify cardiovascular risks from in-development drugs to help inform appropriate trial design and pharmacovigilance strategies. This study uses the Mendelian randomization (MR) approach to study the causal effects of 9 cardiovascular risk factors on ischemic stroke risk both independently and by mediation, followed by an interrogation of the implicated expression quantitative trait loci (eQTLs) to determine if the enriched pathways can explain the adverse stroke events observed with ICI or JAKi treatment. Genetic predisposition to higher systolic blood pressure (SBP), diastolic blood pressure (DBP), body mass index (BMI), waist-to-hip ratio (WHR), low-density lipoprotein cholesterol (LDL), triglycerides (TG), type 2 diabetes (T2DM), and smoking index were associated with higher ischemic stroke risk. The associations of genetically predicted BMI, WHR, and TG on the outcome were attenuated after adjusting for genetically predicted T2DM [BMI: 53.15% mediated, 95% CI 17.21%–89.10%; WHR: 42.92% (4.17%–81.67%); TG: 72.05% (10.63%–133.46%)]. JAKis, programmed cell death protein 1 and programmed death ligand 1 inhibitors were implicated in the pathways enriched by the genes related to the instruments for each of SBP, DBP, WHR, T2DM, and LDL. Overall, MR mediation analyses support the role of T2DM in mediating the effects of BMI, WHR, and TG on ischemic stroke risk and follow-up pathway enrichment analysis highlights the utility of this approach in the early identification of potential harm from drugs.

Item Type:Articles
Additional Information:SP is supported by the British Heart Foundation Centre of Excellence Award at University of Glasgow (RE/18/6/34217) and the UKRI Strength in Places Fund (SIPF00007/1). DG is supported by the British Heart Foundation Centre of Research Excellence at Imperial College London (RE/18/4/34215).
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Padmanabhan, Professor Sandosh and LE, NHU NGOC and Du Toit, Ms Clea
Authors: Le, N. N., Tran, T. Q. B., Du Toit, C., Gill, D., and Padmanabhan, S.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:Frontiers in Cardiovascular Medicine
Publisher:Frontiers Media
ISSN:2297-055X
ISSN (Online):2297-055X
Copyright Holders:Copyright © 2023 Le, Tran, du Toit, Gill and Padmanabhan
First Published:First published in Frontiers in Cardiovascular Medicine 10: 1116799
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
303944BHF Centre of ExcellenceColin BerryBritish Heart Foundation (BHF)RE/18/6/34217CAMS - Cardiovascular Science